Compare · AZYO vs ILMN
AZYO vs ILMN
Side-by-side comparison of Aziyo Biologics Inc. (AZYO) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZYO and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN carries a market cap of $30.34B.
- ILMN has hit the wire 14 times in the past 4 weeks while AZYO has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 1 for AZYO).
- Company
- Aziyo Biologics Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- -
- $30.34B
- 1M return
- -
- -29.07%
- 1Y return
- -
- +67.07%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2000
- News (4w)
- 0
- 14
- Recent ratings
- 1
- 25
Aziyo Biologics Inc.
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest AZYO
- SEC Form SC 13G filed by Aziyo Biologics Inc.
- SEC Form 424B3 filed by Aziyo Biologics Inc.
- SEC Form SC 13G/A filed by Aziyo Biologics Inc. (Amendment)
- SEC Form 4 filed by Mills C Randal
- SEC Form 4 filed by Ferguson Matthew
- SEC Form 4 filed by Williams Michelle Leroux
- Aziyo Biologics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- SEC Form S-8 filed by Aziyo Biologics Inc.
- Aziyo Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Aziyo Biologics Inc. filed SEC Form 8-K: Other Events
Latest ILMN
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.
- Director Meister Keith A. sold $61,093,041 worth of shares (280,091 units at $218.12) (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $58,142 worth of shares (267 units at $217.76), decreasing direct ownership by 2% to 14,029 units (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 360 shares, decreasing direct ownership by 0.88% to 40,567 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D covered exercise/tax liability with 150 shares, decreasing direct ownership by 1% to 14,296 units (SEC Form 4)
- SVP, Chief People Officer Leckman Patricia covered exercise/tax liability with 208 shares, decreasing direct ownership by 0.98% to 21,120 units (SEC Form 4)
- Chief of Global Operations Pegels Kevin Carl covered exercise/tax liability with 604 shares, decreasing direct ownership by 2% to 28,434 units (SEC Form 4)
- Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
- Director Meister Keith A. sold $66,560,212 worth of shares (281,433 units at $236.50) (SEC Form 4)
- Illumina selected to help bring precision medicine into everyday healthcare in Singapore